Slide 1: Evolent Health, Inc. Supplemental Investor Presentation
Confidential – Do Not Distribute1 Evolent Health, Inc. Supplemental Investor Presentation November 9, 2022 Exhibit 99.1
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). A forward-looking statement is a statement t
Slide 3: Q3 2022 Key Highlights
3 Q3 2022 Key Highlights GROWTH PROFITABILITY CAPITAL GUIDANCE • Strong consolidated revenue: $353M, +58.5% y/y • Three new Clinical Segment operating partnerships, and several cross and upsells across the portfolio, including Vital Decisions • Macro environment a tailwind for pipeline development a
Slide 4: Recent History: Significant Clinical Segment Growth Momentum
4 Recent History: Significant Clinical Segment Growth Momentum $130.2 $147.2 $159.6 $161.1 $190.2 $227.6 $245.3 Q1 2021 Q2 Q3 Q4 Q1 2022 Q2 Q3 Clinical Segment Revenue ($ in millions) 44% Reported CAGR >41% Organic Top Line CAGR Strong Sales Execution Across 2022 • New Regional and State Partners –
Slide 5: Why Evolent Health? Investment Considerations
5 Why Evolent Health? Investment Considerations Execution Drives Shareholder Value Efficient Capital Allocation Strong and Expanding Margins Compelling Long-Term Organic Growth Commitment to Shareholder Value
Slide 6: Appendix
Confidential – Do Not Distribute6 Appendix
Slide 7: How We Calculate Segment Drivers: PMPM, Lives and Cases
7 How We Calculate Segment Drivers: PMPM, Lives and Cases Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements.
Slide 8: Appendix A – Evolent Health, Inc. Adjusted EBITDA Reconciliation
8 Appendix A – Evolent Health, Inc. Adjusted EBITDA Reconciliation Consolidated Clinical Solutions Evolent Health Services Corporate Guidance ($ in millions) Q3 2022 Q3 2021 LTM Q3 2022 LTM Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021 Q3 2022 Q3 2021 2022 Net income (loss) attributable to common sharehol
Slide 9: Appendix B – Net Debt to LTM Adjusted EBITDA
9 Appendix B – Net Debt to LTM Adjusted EBITDA 1. Principal amounts of short-term and long-term debt and comprised of $- and $26.7M of 2021 Notes, $24.3M and $117.1M of 2024 Notes, $172.5M and $172.5M of 2025 Notes and $225.0M and $- of 2022 Credit Facilities as of September 30, 2022 and 2021, respe